Guardian Drug Co. Inc. Faces Nationwide Recall for Metallic Contamination in Calcium Carbonate Antacids
Guardian Drug Co. Inc. has initiated a nationwide Class II recall (D-0565-2026) for CAREone Extra Strength Calcium Antacid (Calcium Carbonate 750 mg) due to metallic particles. This event, coupled with recent similar recalls, signals systemic quality control issues. Procurement and regulatory teams must reassess supply chain risks and diversify sourcing for antacid products to mitigate disruption.
FDA Findings: Metallic Particle Contamination in Calcium Carbonate Antacids
This analysis details the Class II voluntary recall, reference number D-0565-2026, initiated by Guardian Drug Co. Inc. on May 28, 2026. The core issue identified is the presence of small metallic particles within chewable tablets of CAREone, EXTRA STRENGTH CALCIUM ANTACID, a Calcium Carbonate 750 mg human Over-the-Counter (OTC) drug. The product, distributed by FOODHOLD U.S.A, LLC, and manufactured by Retail Business Services, LLC., was distributed nationwide across the U.S. The affected lots are specifically identified as 1276118 and 1276119, both carrying an expiration date of January 2029. This contamination represents a critical quality control failure, posing potential ingestion hazards to consumers, which is a significant concern for patient safety. For procurement directors, this incident highlights the imperative for rigorous supplier qualification and ongoing audit programs, particularly for high-volume OTC products where manufacturing consistency is paramount. Regulatory affairs heads must note the FDA's Class II classification, which signifies a situation where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This event underscores the critical need for robust foreign matter detection protocols and quality assurance throughout the entire pharmaceutical manufacturing process, from raw material inspection to finished product release.
Operational Impact: Guardian Drug Co. Inc.'s Role in OTC Antacid Supply Chain
Guardian Drug Co. Inc., operating from its Dayton, NJ facility located at 2 Charles Ct, 08810-1508, plays a significant role in the Over-the-Counter (OTC) pharmaceutical sector, particularly in the distribution and recall management of antacid products. While Retail Business Services, LLC. is identified as the manufacturer for the CAREone Extra Strength Calcium Antacid (Calcium Carbonate 750 mg) product under recall, Guardian Drug Co. Inc. is the firm initiating this voluntary Class II recall. This operational structure implies a complex supply chain where Guardian Drug Co. Inc. assumes responsibility for the quality and safety of products reaching the market under its recall purview, even if manufactured by a third party. For supply chain VPs, this event signals potential disruptions in the availability of private-label or distributed Calcium Carbonate antacids across the U.S. market. Business development executives evaluating partnerships in the OTC space must consider the implications of such quality incidents on brand reputation and continuity of supply, particularly when dealing with firms responsible for product recalls across multiple brands. The nationwide distribution pattern of the affected product further amplifies the potential market impact, requiring immediate action from all stakeholders involved in the antacid supply chain.
Supply Chain Exposure: Risks for Retailers and Distributors of Antacids
The nationwide distribution of the affected CAREone, EXTRA STRENGTH CALCIUM ANTACID (Calcium Carbonate 750 mg) chewable tablets exposes a broad network of retailers and distributors, including FOODHOLD U.S.A, LLC, to significant commercial and reputational risks. The presence of metallic particles in an ingestible OTC drug necessitates immediate removal from shelves, leading to substantial inventory write-offs, complex reverse logistics costs, and potential erosion of consumer trust in the CAREone brand and associated retail partners. Such incidents can have lasting impacts on brand loyalty and market perception. For procurement directors managing private label portfolios, this incident mandates an urgent and comprehensive review of quality agreements and audit schedules with all contract manufacturers and distributors of similar antacid products. Regulatory affairs teams must prepare for an influx of potential consumer complaints and inquiries, requiring transparent communication and efficient recall management protocols. This event underscores that even for widely used, seemingly low-risk molecules like Calcium Carbonate, stringent quality control from manufacturing through distribution is non-negotiable. The financial implications extend beyond the immediate recall costs, potentially impacting future sales volumes and market share for affected retail partners and distributors.
Alternative Sourcing Strategies for Calcium Carbonate API
Given the ongoing Class II recall of Calcium Carbonate 750 mg chewable tablets due to metallic contamination, procurement teams must proactively assess and fortify their sourcing strategies for antacid APIs and finished dosage forms. While the ChemLifeIntel Knowledge Graph does not specify alternative suppliers for this particular event, Calcium Carbonate is a widely available active pharmaceutical ingredient (API) globally, used in various pharmaceutical and nutraceutical applications. Companies should immediately initiate or accelerate qualification processes for new suppliers to diversify their supply base and mitigate future disruption risks. Key considerations for alternative supplier selection include a proven track record of cGMP compliance, robust quality management systems, and a transparent audit history. Geographic diversification, exploring suppliers from regions such as India, China, and Europe, can further enhance supply chain resilience and reduce reliance on single-source origins. Qualification timelines for new API suppliers can range significantly, typically from 6 to 18 months, emphasizing the urgency for business development executives to identify and engage potential partners now to ensure continuity of supply for critical OTC medications like antacids. Proactive engagement can prevent future supply gaps and maintain market presence.
Guardian Drug Co. Inc.'s Recurring Quality Challenges and Regulatory History
This current Class II recall for CAREone Extra Strength Calcium Antacid is not an isolated incident for Guardian Drug Co. Inc., revealing a concerning pattern of similar quality control failures within their distributed product portfolio. The ChemLifeIntel Knowledge Graph indicates that just prior to this event, on June 10, 2026, Guardian Drug Co. Inc. faced two other nationwide Class II recalls for metallic contamination in antacid products: one specifically for "Tums Antacid" and another for "HyVee Antacid." These parallel events, all involving metallic particles in chewable antacids, strongly indicate systemic deficiencies in Guardian Drug Co. Inc.'s quality management or manufacturing oversight processes. For regulatory affairs heads, this trend suggests heightened scrutiny from the FDA. A pattern of recurring quality issues can lead to more severe enforcement actions beyond voluntary recalls, such as formal Warning Letters, increased inspection frequency, or even Import Alerts if the issues involve foreign manufacturing sites. Supply chain VPs must recognize that a supplier exhibiting such a consistent pattern of quality issues presents a significant and escalating risk to product integrity and supply continuity across their entire portfolio of distributed products. This history necessitates a thorough re-evaluation of all contracts, quality agreements, and risk assessments with Guardian Drug Co. Inc. to protect brand reputation and consumer safety.
Remediation and Outlook: Heightened Scrutiny for Antacid Supply Chain
The Class II recall (D-0565-2026) for CAREone Extra Strength Calcium Antacid remains classified as "Ongoing," indicating that Guardian Drug Co. Inc. is still actively managing the withdrawal of affected lots (1276118, 1276119) from the U.S. market. The immediate priority for Guardian Drug Co. Inc. and its manufacturing partner, Retail Business Services, LLC., must be to conduct a comprehensive root cause analysis to definitively identify how metallic particles entered the Calcium Carbonate 750 mg chewable tablets and to implement robust corrective and preventive actions (CAPA). This investigation must be thorough and scientifically sound to prevent recurrence. For regulatory affairs teams, this means preparing for potential FDA inspections to verify the effectiveness of these CAPA measures. The recurring nature of metallic contamination issues, as evidenced by the recent recalls for Tums and HyVee antacids, suggests that the FDA will likely maintain a heightened level of oversight on Guardian Drug Co. Inc.'s operations. Business development executives should anticipate increased due diligence requirements for any future partnerships involving Guardian Drug Co. Inc., while procurement directors should factor in the potential for prolonged supply chain instability and the necessity of qualifying alternative sources for antacid products to safeguard market supply and minimize business interruption.